Literature DB >> 34817826

Predictive Performance of Published Tacrolimus Population Pharmacokinetic Models in Thai Kidney Transplant Patients.

Janthima Methaneethorn1,2, Manupat Lohitnavy3,4, Kamonwan Onlamai5, Nattawut Leelakanok6.   

Abstract

BACKGROUND AND
OBJECTIVE: Tacrolimus is a narrow therapeutic index drug with high pharmacokinetic variability, and several tacrolimus population pharmacokinetic (PopPK) models were developed to guide individualized drug dosing. These models, however, may not perform well in other clinical settings. Therefore, we aimed to assess the predictive ability of published tacrolimus PopPK models using a dataset of Thai kidney transplant patients.
METHODS: The external dataset was retrospectively collected from medical records of Bhumibol Adulyadej Hospital, Thailand. Published tacrolimus PopPK models were systematically searched from PubMed, Science Direct, CINAHL Complete, and Scopus databases. Models conducted using a nonlinear mixed-effects approach with covariate resemblance to our external dataset were selected. The external dataset consisted of Thai kidney transplant patients receiving oral immediate- or extended-release tacrolimus formulations twice or once daily, respectively. Accuracy and precision of predicted concentrations were evaluated using mean absolute prediction error (MAPE), root mean square error (RMSE), and goodness of fit plots.
RESULTS: Only three models produced acceptable population predictions with the MAPE of < 50%. By using the Bayesian posthoc estimate of individual pharmacokinetic parameters, all models well performed with the MAPE and RMSE of < 30% and 40%, respectively, except two models; one could not successfully converge and the other substantially underpredicted tacrolimus concentrations.
CONCLUSION: We evaluated ten tacrolimus PopPK models, and eight models resulted in satisfactorily individual predicted tacrolimus concentrations in Thai kidney transplant patients and may be used to aid tacrolimus dose adjustment along with a clinical judgment.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34817826     DOI: 10.1007/s13318-021-00735-8

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  36 in total

Review 1.  Pharmacokinetic models to assist the prescriber in choosing the best tacrolimus dose.

Authors:  Jean-Baptiste Woillard; Franck Saint-Marcoux; Jean Debord; Anders Åsberg
Journal:  Pharmacol Res       Date:  2018-02-13       Impact factor: 7.658

2.  Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients.

Authors:  Wei Zhao; May Fakhoury; Véronique Baudouin; Thomas Storme; Anne Maisin; Georges Deschênes; Evelyne Jacqz-Aigrain
Journal:  Eur J Clin Pharmacol       Date:  2012-06-17       Impact factor: 2.953

Review 3.  Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients.

Authors:  P E Wallemacq; R K Verbeeck
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients.

Authors:  Khaled Benkali; Aurelie Prémaud; Nicolas Picard; Jean-Philippe Rérolle; Olivier Toupance; Guillaume Hoizey; Alain Turcant; Florence Villemain; Yannick Le Meur; Pierre Marquet; Annick Rousseau
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 6.  Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet?

Authors:  Emily Brooks; Susan E Tett; Nicole M Isbel; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2016-11       Impact factor: 6.447

7.  Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients.

Authors:  W Zhao; V Elie; G Roussey; K Brochard; P Niaudet; V Leroy; C Loirat; P Cochat; S Cloarec; J L André; F Garaix; A Bensman; M Fakhoury; E Jacqz-Aigrain
Journal:  Clin Pharmacol Ther       Date:  2009-10-28       Impact factor: 6.875

Review 8.  Clinical pharmacokinetics of tacrolimus.

Authors:  R Venkataramanan; A Swaminathan; T Prasad; A Jain; S Zuckerman; V Warty; J McMichael; J Lever; G Burckart; T Starzl
Journal:  Clin Pharmacokinet       Date:  1995-12       Impact factor: 6.447

Review 9.  Population Pharmacokinetics of Tacrolimus in Transplant Recipients: What Did We Learn About Sources of Interindividual Variabilities?

Authors:  Olivia Campagne; Donald E Mager; Kathleen M Tornatore
Journal:  J Clin Pharmacol       Date:  2018-10-29       Impact factor: 3.126

Review 10.  Tacrolimus Pharmacokinetic and Pharmacogenomic Differences between Adults and Pediatric Solid Organ Transplant Recipients.

Authors:  Kwaku Marfo; Jerry Altshuler; Amy Lu
Journal:  Pharmaceutics       Date:  2010-09-09       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.